How to get all trials reported : audit, better data, and individual accountability by Goldacre, B

The WHO joint statement from funders on trials transparency by Goldacre, B

Prevalence of clinical trial status discrepancies: A cross-sectional study of 10,492 trials registered on both ClinicalTrials.gov and the European Union Clinical Trials Register by Fleminger, J, Goldacre, B

OpenTrials: towards a collaborative open database of all available information on all clinical trials by Goldacre, B, Gray, J

Improving, and auditing, access to clinical trial results. by Goldacre, B, Heneghan, C

You can now search FDA approval documents easily at fda.opentrials.net by Goldacre, B, Turner, E

Trends and variation in data quality and availability on the European Union Clinical Trials Register: A cross-sectional study by Devito, NJ, Goldacre, B

Reply to Comment on ‘Impact of NICE guidance on tamoxifen prescribing in England 2011–2017: an interrupted time series analysis” by Curtis, H, Goldacre, B

OpenPrescribing: normalised data and software tool to research trends in English NHS primary care prescribing 1998-2016 by Curtis, H, Goldacre, B

Prescription data for open toe sandals syndrome. by Croker, R, Goldacre, B

The TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions by Powell-Smith, A, Goldacre, B

Catalogue of bias: publication bias by Goldacre, B, DeVito, NJ

Evaluation of compliance with legal requirements under the FDA Amendments Act 2007 for timely registration of clinical trials, data verification, delayed reporting, and trial docum... by DeVito, N, Goldacre, B

Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study by DeVito, NJ, Bacon, S, Goldacre, B

Why did some practices not implement new antibiotic prescribing guidelines on urinary tract infection? A cohort study and survey in NHS England primary care by Croker, R, Walker, A, Goldacre, B

Pregabalin: what the patent litigation means for doctors and drug companies by Smyth, D, Croker, R, Goldacre, B

Why clinical trial outcomes fail to translate into benefits for patients. by Heneghan, C, Goldacre, B, Mahtani, K

Authors’ reply to Aiyenigba and Weeks, Bahadur and colleagues, and Griffin and colleagues by Heneghan, C, Spencer, E, Goldacre, B

Impact of Chief Medical Officer activity on prescribing of antibiotics in England: an interrupted time series analysis by Walker, A, Curtis, H, Goldacre, B

The PRINTO juvenile dermatomyositis trial by Dale, A, Milosevic, I, Goldacre, B